Skip to main content
Erschienen in: The International Journal of Cardiovascular Imaging 2/2024

09.11.2023 | Original Paper

Cardiac scintigraphy and echocardiography assessment in the diagnosis of transthyretin cardiac amyloidosis

verfasst von: María del Carmen Mallón Araujo, Estephany Abou Jokh Casas, Charigan Abou Jokh Casas, María Amparo Martinez Monzonis, Álvaro Ruibal Morell, Virginia Pubul Núñez

Erschienen in: The International Journal of Cardiovascular Imaging | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

The aim is to evaluate the diagnostic yield of echocardiography and [99mTc]Tc-DPD scintigraphy in the detection of amyloid cardiomyopathy (CM) and define potential prognostic echocardiographic parameters. 133 patients were retrospectively studied, from 2016 to 2021, with a mean age of 80.2 ± 7.5 years. The final diagnosis was established according to international consensus. Patients had a transthoracic echocardiogram (TTE) and [99mTc]Tc-DPD scintigraphy; RWT, E/e, LS, TAPSE, SAB, and IWT scores were calculated. All patients with ATTR-CM were classified into 3 prognostic stages and were compared with Perugini grades and echocardiographic parameters. CM was confirmed in 85 cases (63.9%), 76 (57.1%) ATTR-CM, and 9 (6.8%) AL-CM. The diagnostic yield of [99mTc]Tc-DPD scintigraphy and echocardiography were calculated, with a sensitivity of 90.7%, specificity of 100%, PPV of 100%, and NPV of 87.2% in myocardial scintigraphy, versus 74.6%, 62.5%, 75.6%, 61.2% in the echocardiogram. According to the IWT score, most patients were classified in the intermediate group; 33 presented with grade 2–3 uptakes. Significant results were obtained when comparing Perugini score with IWT (p: 0.02) and SAB (p: 0.03); and between biomarkers stages and LVEF (p: 0.028), E/e´ (p: 0.001), and GLS% (p: 0.022). [99mTc]Tc-DPD scintigraphy is superior in diagnosing CA. SAB could be the most reliable parameter in an early diagnostic phase, showing a strong correlation with Perugini grades 2 and 3.
Literatur
1.
Zurück zum Zitat Singh V, Falk R, Di Carli M, Kijewski M, Rapezzi C, Dorbala S (2019) State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol 26(1):158–173CrossRefPubMed Singh V, Falk R, Di Carli M, Kijewski M, Rapezzi C, Dorbala S (2019) State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol 26(1):158–173CrossRefPubMed
2.
Zurück zum Zitat Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk R, Ferrari V (2019) ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging. J Card Fail 25(11):e1–e39CrossRefPubMed Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk R, Ferrari V (2019) ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base and standardized methods of imaging. J Card Fail 25(11):e1–e39CrossRefPubMed
3.
Zurück zum Zitat Beretta M, Ramírez J, Kapitán M, López A, Mut F (2018) Amiloidosis cardíaca: valor del diagnóstico molecular con radiotrazadores. Rev Urug Cardiol 33(2):236–240 Beretta M, Ramírez J, Kapitán M, López A, Mut F (2018) Amiloidosis cardíaca: valor del diagnóstico molecular con radiotrazadores. Rev Urug Cardiol 33(2):236–240
4.
Zurück zum Zitat Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba M, Lopez-Sainz A, Giannoni A (2020) Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13(4):909–920CrossRefPubMed Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba M, Lopez-Sainz A, Giannoni A (2020) Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging 13(4):909–920CrossRefPubMed
5.
Zurück zum Zitat Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42(16):1554–1568CrossRefPubMedPubMedCentral Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A et al (2021) Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J 42(16):1554–1568CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 133(24):2404–12CrossRefPubMed Gillmore J, Maurer M, Falk R, Merlini G, Damy T, Dispenzieri A (2016) Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 133(24):2404–12CrossRefPubMed
7.
Zurück zum Zitat Povar-Echeverría M, Auquilla-Clavijo P, Povar-Marco B, Moreno-Esteban E, Figueras-Villalba M (2020) Cardiac amyloidosis: a review of a series of cases. Arch Cardiol Mex 90(3):259–265PubMed Povar-Echeverría M, Auquilla-Clavijo P, Povar-Marco B, Moreno-Esteban E, Figueras-Villalba M (2020) Cardiac amyloidosis: a review of a series of cases. Arch Cardiol Mex 90(3):259–265PubMed
8.
Zurück zum Zitat González-López E, López-Sainz A, Garcia-Pavia P (2017) Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza Rev Esp Cardiol 70(11):991–1004CrossRef González-López E, López-Sainz A, Garcia-Pavia P (2017) Diagnóstico y tratamiento de la amiloidosis cardiaca por transtiretina. Progreso y esperanza Rev Esp Cardiol 70(11):991–1004CrossRef
9.
Zurück zum Zitat Martinez-Naharro A, Baksi A, Hawkins P, Fontana M (2020) Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol 17(7):413–426CrossRefPubMed Martinez-Naharro A, Baksi A, Hawkins P, Fontana M (2020) Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol 17(7):413–426CrossRefPubMed
10.
Zurück zum Zitat Ruberg F, Grogan M, Hanna M, Kelly J, Maurer M (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872–2891CrossRefPubMedPubMedCentral Ruberg F, Grogan M, Hanna M, Kelly J, Maurer M (2019) Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol 73(22):2872–2891CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Haro-del Moral F, Pubul-Nuñez V, Casáns-Tormo I, Jiménez-Heffernan A, Ruano-Pérez R (2020) Gammagrafía cardíaca con 99mTc-difosfonatos en la amiloidosis cardíaca. Rev Esp Med Nucl Imagen Mol 39(4):254–266PubMed Haro-del Moral F, Pubul-Nuñez V, Casáns-Tormo I, Jiménez-Heffernan A, Ruano-Pérez R (2020) Gammagrafía cardíaca con 99mTc-difosfonatos en la amiloidosis cardíaca. Rev Esp Med Nucl Imagen Mol 39(4):254–266PubMed
13.
Zurück zum Zitat Hanna M, Ruberg F, Maurer M, Dispenzieri A, Dorbala S, Falk R et al (2020) Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol 75(22):2851–2862CrossRefPubMed Hanna M, Ruberg F, Maurer M, Dispenzieri A, Dorbala S, Falk R et al (2020) Cardiac scintigraphy with technetium-99m-labeled bone-seeking tracers for suspected amyloidosis: JACC review topic of the week. J Am Coll Cardiol 75(22):2851–2862CrossRefPubMed
14.
Zurück zum Zitat Hotta V, Giorgi M, Fernandes F, Abduch M, Falcão A, Mady C (2020) Cardiac amyloidosis: non-invasive diagnosis. Rev Assoc Med Bras 66(3):345–352CrossRefPubMed Hotta V, Giorgi M, Fernandes F, Abduch M, Falcão A, Mady C (2020) Cardiac amyloidosis: non-invasive diagnosis. Rev Assoc Med Bras 66(3):345–352CrossRefPubMed
15.
Zurück zum Zitat Rubin J, Maurer M (2020) Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med 71:203–219CrossRefPubMed Rubin J, Maurer M (2020) Cardiac amyloidosis: overlooked, underappreciated, and treatable. Annu Rev Med 71:203–219CrossRefPubMed
16.
Zurück zum Zitat Urbano-Moral J, Gangadharamurthy D, Comenzo R, Pandian N, Patel A (2015) Ecocardiografía speckle tracking (rastreo de marcas) tridimensional en la amiloidosis cardiaca de cadenas ligeras: estudio de los parámetros de mecánica miocárdica ventricular izquierda y derecha. Rev Esp Cardiol 68(8):657–664CrossRefPubMed Urbano-Moral J, Gangadharamurthy D, Comenzo R, Pandian N, Patel A (2015) Ecocardiografía speckle tracking (rastreo de marcas) tridimensional en la amiloidosis cardiaca de cadenas ligeras: estudio de los parámetros de mecánica miocárdica ventricular izquierda y derecha. Rev Esp Cardiol 68(8):657–664CrossRefPubMed
17.
Zurück zum Zitat Pericet-Rodríguez C, López-Aguilera J, Durán-Torralba C, Castillo-Domínguez J, Ruiz-Ortiz M, Perea-Armijo J et al (2022) Caracterización y pronóstico del paciente con amiloidosis cardiaca: experiencia de un centro. Rev Esp Cardiol 57(1):14–23 Pericet-Rodríguez C, López-Aguilera J, Durán-Torralba C, Castillo-Domínguez J, Ruiz-Ortiz M, Perea-Armijo J et al (2022) Caracterización y pronóstico del paciente con amiloidosis cardiaca: experiencia de un centro. Rev Esp Cardiol 57(1):14–23
18.
Zurück zum Zitat González-López E, Gagliardi C, Dominguez F, Quarta C, de Haro-Del MF, Milandri A et al (2017) Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 38(24):1895–1904CrossRefPubMed González-López E, Gagliardi C, Dominguez F, Quarta C, de Haro-Del MF, Milandri A et al (2017) Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths. Eur Heart J 38(24):1895–1904CrossRefPubMed
19.
Zurück zum Zitat Barge-Caballero G, Vázquez-García R, Barge-Caballero E, Couto-Mallón D, Paniagua-Martín M, Barriales-Villa R et al (2021) Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors. Med Clin (Barc) 156(8):369–378CrossRefPubMed Barge-Caballero G, Vázquez-García R, Barge-Caballero E, Couto-Mallón D, Paniagua-Martín M, Barriales-Villa R et al (2021) Light chain and transthyretin cardiac amyloidosis: Clinical characteristics, natural history and prognostic factors. Med Clin (Barc) 156(8):369–378CrossRefPubMed
20.
Zurück zum Zitat Jain A, Zahra F (2021) Transthyretin amyloid cardiomyopathy (ATTR-CM). StatPearls, Tampa Jain A, Zahra F (2021) Transthyretin amyloid cardiomyopathy (ATTR-CM). StatPearls, Tampa
21.
Zurück zum Zitat Garcia-Pavia P, Domínguez F, Gonzalez-Lopez E (2021) Transthyretin amyloid cardiomyopathy. Med Clin (Barc) 156(3):126–134CrossRefPubMed Garcia-Pavia P, Domínguez F, Gonzalez-Lopez E (2021) Transthyretin amyloid cardiomyopathy. Med Clin (Barc) 156(3):126–134CrossRefPubMed
22.
Zurück zum Zitat Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk R, Ferrari V et al (2021) Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 28(4):1769–1774CrossRefPubMed Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk R, Ferrari V et al (2021) Addendum to ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Nucl Cardiol 28(4):1769–1774CrossRefPubMed
Metadaten
Titel
Cardiac scintigraphy and echocardiography assessment in the diagnosis of transthyretin cardiac amyloidosis
verfasst von
María del Carmen Mallón Araujo
Estephany Abou Jokh Casas
Charigan Abou Jokh Casas
María Amparo Martinez Monzonis
Álvaro Ruibal Morell
Virginia Pubul Núñez
Publikationsdatum
09.11.2023
Verlag
Springer Netherlands
Erschienen in
The International Journal of Cardiovascular Imaging / Ausgabe 2/2024
Print ISSN: 1569-5794
Elektronische ISSN: 1875-8312
DOI
https://doi.org/10.1007/s10554-023-02987-8

Weitere Artikel der Ausgabe 2/2024

The International Journal of Cardiovascular Imaging 2/2024 Zur Ausgabe

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

GLP-1-Agonisten können Fortschreiten diabetischer Retinopathie begünstigen

24.05.2024 Diabetische Retinopathie Nachrichten

Möglicherweise hängt es von der Art der Diabetesmedikamente ab, wie hoch das Risiko der Betroffenen ist, dass sich sehkraftgefährdende Komplikationen verschlimmern.

TAVI versus Klappenchirurgie: Neue Vergleichsstudie sorgt für Erstaunen

21.05.2024 TAVI Nachrichten

Bei schwerer Aortenstenose und obstruktiver KHK empfehlen die Leitlinien derzeit eine chirurgische Kombi-Behandlung aus Klappenersatz plus Bypass-OP. Diese Empfehlung wird allerdings jetzt durch eine aktuelle Studie infrage gestellt – mit überraschender Deutlichkeit.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.